Latest Research And Development News

Page 20 of 115
Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.
Ada Torres
Ada Torres
27 Aug 2026
Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.
Ada Torres
Ada Torres
27 Aug 2026
Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.
Victor Sage
Victor Sage
27 Aug 2026
Global Health Limited trimmed its FY26 net loss by 12.5% to A$758,220, driven by a 5.5% lift in recurring SaaS revenue and a 20% cut in employee costs aided by AI integration, though going concern risks remain.
Sophie Babbage
Sophie Babbage
27 Aug 2026
Ainsworth Game Technology’s first half 2026 results reveal a sharp revenue drop driven by North American and Latin American market pressures, offset partially by Asia Pacific growth and a key patent licensing deal.
Victor Sage
Victor Sage
26 Aug 2026
Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.
Ada Torres
Ada Torres
26 Aug 2026
Calix Limited posted a 16% revenue increase to $39.2 million in FY26 driven by strong growth in its Magnesia business, while reporting a substantial net loss of $51 million largely due to a one-off impairment. The company advanced key industrial decarbonisation projects and strengthened strategic partnerships, focusing on capital-light commercialisation.
Victor Sage
Victor Sage
26 Aug 2026
Prescient Therapeutics (ASX:PTX) has opened a $7 million Share Purchase Plan at a significant discount to advance its lead cancer therapy PTX-100 beyond a pivotal Dose Optimisation Committee review in late 2026.
Ada Torres
Ada Torres
26 Aug 2026
Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.
Ada Torres
Ada Torres
26 Aug 2026
NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.
Ada Torres
Ada Torres
25 Aug 2026
Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.
Ada Torres
Ada Torres
25 Aug 2026
Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.
Ada Torres
Ada Torres
25 Aug 2026

Browse the archive

Full archive